Morgan Stanley: Maintains Guangzhou Baiyunshan Pharmaceutical Holdings (00874) "in-line with the market" rating, target price lowered to HK$21.4

Morgan Stanley has released a research report, stating that after the announcement of the third quarter performance by Guangzhou Baiyunshan Pharmaceutical Holdings (00874), it has decided to lower its profit forecast for the company from this year to 2030 by 3% to 7%. The earnings per share forecast from this year to 2026 is adjusted to 2.25 yuan, 1.87 yuan, and 1.96 yuan respectively, and the sales forecast is also lowered. The target price for Guangzhou Baiyunshan Pharmaceutical Holdings is revised slightly down from 21.7 Hong Kong dollars to 21.4 Hong Kong dollars, with a "synchronize with the market" rating maintained.